The Rising Incidences of CVDs are Propelling the Growth of the Propranolol Drug Market in the APAC Region!

The Asia Pacific Propranolol Drug market is a significant contributor to the global propranolol drug market, which is expected to grow significantly in the coming years. The Asia Pacific region is home to some of the world’s most populous countries, such as China and India, which present a vast market for propranolol drug-based medications. The increasing prevalence of chronic diseases such as cardiovascular diseases, which require the use of propranolol drug-based medications is among the important reasons for the market growth of the propranolol drug market in the region. For instance, as per the Australian Institute of Health and Welfare, from 2020 to 2021, Cardiac Heart Disease was the predominant diagnosis in approximately 160,000 hospitalizations. Of these, 36% were due to myocardial infarction and 22% were due to angina pectoris.

Access sample report (including graphs, charts, and figures): https://univdatos.com/get-a-free-sample-form-php/?product_id=44139

Further, the Asia-Pacific Propranolol Drug Market is expected to grow at a strong CAGR of 4% during the forecast period (2022-2030). The growing trend toward personalized medicine involves the use of propranolol drug-based medications that are tailored to the specific needs of individual patients.

APAC Propranolol Drug Market Revenue (2020-2030)- USD Mn

Based on application, the market is segmented into hypertension, angina, heart rhythm management, and others. As per our analysis, the angina segment is expected to grow at a higher CAGR during the forecast period. The rising prevalence of cardiac disorders and coronary artery blockage and angina is the main symptom of the diseases attributed to the fast growth of the propranolol market.

Based on the type, the market is segmented into oral and intravenous. As per our analysis, the oral segment held the dominant share in 2021. Oral medicines are preferable for patients as they are easy to consume and chemically as well as biologically more stable. Further, these drugs are cost-efficient as these drugs don’t undergo sterilization procedures which is also an important factor for the large share of the segment.

Based on distribution channels, the market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. As per our analysis, the hospital pharmacies segment acquired a major share in 2021. This is mainly due to the easily available medicines by the hospital pharmacies during any emergency situation. Further, hospital pharmacies are available inside the healthcare institution which is an important factor for the accessibility of the pharmacy during treatment is also an important factor driving the growth of hospital pharmacies.

For a detailed analysis of Global Propranolol Drug Market browse through – https://univdatos.com/report/propranolol-drug-market/

Global Propranolol Drug Market Segmentation

Market Insight, by Application

• Hypertension
• Angina
• Heart Rhythm Management
• Others

Market Insight, by Type

• Oral
• Intravenous

Market Insight, by Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Market Insight, by Region

• North America
  • U.S.
  • Canada
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • India
  • Rest of APAC
• Rest of the World

Top Company Profiles

• Pierre Fabre Group
• Hikma Pharmaceuticals PLC• Viatris Inc• GSK plc• Baxter• Teva Pharmaceutical Industries Ltd.• ANI Pharmaceuticals, Inc.• Amneal Pharmaceuticals LLC• Fresenius Kabi AG• Par Pharmaceutical